News

QT Analysis: Taiwan TFDA Upgrades IVD Regulatory Requirements for CRP and AST Systems – How Should Companies Adjust Their Market Strategy? – September/October 2026

QT Analysis: Taiwan TFDA Upgrades IVD Regulatory Requirements for CRP and AST Systems – How Should Companies Adjust Their Market Strategy? – September/October 2026

  • 2026-10-27 05:30:31

Taiwan's Food and Drug Administration (TFDA) released new guidance in August and September 2026 for C-Reactive Protein (CRP) assays and Antimicrobial Susceptibility Testing (AST) systems, two Class II in vitro diagnostic (IVD) device categories. The updates require CRM470 calibration traceability and additional clinical data for hsCRP cardiovascular risk claims, as well as multi-center accuracy studies for AST systems. This analysis reviews the key changes, their impact on registration timelines and market competition, and the value of an early technical documentation gap analysis.

More
Philippines: PFDA Updates Draft Guidelines on Medical Device Labeling Requirements – September/October 2026

Philippines: PFDA Updates Draft Guidelines on Medical Device Labeling Requirements – September/October 2026

  • 2026-10-27 04:18:58

The Food and Drug Administration of the Philippines (PFDA) has released a draft FDA Circular proposing detailed guidelines for medical device labeling in the Philippines. The draft provides more specific requirements on labeling content and placement, device-specific labeling, electronic labeling, and regulatory actions for non-compliance. It also proposes a two-year transition period for medical devices already registered and available in the Philippine market. While the Circular remains in draft form, it reflects PFDA's direction toward more detailed and specific medical device labeling requirements.

More
Philippines: PFDA Circulates Revised Draft Regulatory Guidelines for Medical Device Software (MDSW) – September/October 2026

Philippines: PFDA Circulates Revised Draft Regulatory Guidelines for Medical Device Software (MDSW) – September/October 2026

  • 2026-10-26 09:52:44

The Food and Drug Administration of the Philippines (PFDA) has circulated a revised draft Circular proposing updated regulatory guidelines for Medical Device Software (MDSW), including AI-enabled MDSW. The draft outlines software qualification criteria, risk-based classification, product authorization pathways, and technical documentation requirements for initial and renewal applications. It also introduces AI-specific requirements covering clinical validation, cybersecurity, risk management, and post-market monitoring. The proposed guidelines aim to strengthen the safety and performance of MDSW throughout its lifecycle. The Circular remains in draft form and is not yet effective.

More
Philippines: An Overview of the Proposed FDA Guidelines on Good Manufacturing Practices (GMP) for Medical Devices – August/September 2026

Philippines: An Overview of the Proposed FDA Guidelines on Good Manufacturing Practices (GMP) for Medical Devices – August/September 2026

  • 2026-09-21 03:23:41

The Philippine Department of Health has released a proposed Administrative Order establishing Good Manufacturing Practice (GMP) guidelines for local medical device and IVD medical device manufacturers. The proposed Order adopts PNS ISO 13485:2019 as the Food and Drug Administration (FDA)'s official GMP guideline and applicable PNS ISO 14644 standards for clean rooms. A two-year transitory period is proposed to allow affected manufacturers to comply with the new requirements once the Order takes effect.

More
THAILAND: Thai FDA – Update Change Notification Details on Levels, Processing Timeframes, Assessment Conditions, and Applicable Fees – July/August 2026

THAILAND: Thai FDA – Update Change Notification Details on Levels, Processing Timeframes, Assessment Conditions, and Applicable Fees – July/August 2026

  • 2026-08-25 08:37:14

Thailand has updated its operational framework for Class 2-4 medical device change notification. Revised processing timelines and fee structures have been established for both standard and expert review pathways. Medical device manufacturers and importers marketing products in Thailand must review the updated criteria, evaluation periods, and associated fees prior to submitting change requests to ensure full regulatory compliance.

More
Philippines: An Overview of the Proposed FDA Guidelines for Variations to Issued Product Authorizations for Medical and Health-Related Devices – June/July 2026

Philippines: An Overview of the Proposed FDA Guidelines for Variations to Issued Product Authorizations for Medical and Health-Related Devices – June/July 2026

  • 2026-07-27 03:42:33

The Philippine FDA has issued a draft Circular proposing a comprehensive risk-based framework for post-approval variations of medical and health-related devices. Key proposed changes include the introduction of risk-based variation classifications, a dedicated variation pathway for medical device software (MDSW), single variation applications for eligible multiple product authorizations, updated submission procedures, and enhanced post-market responsibilities for Marketing Authorization Holders (MAHs) and retailers. The draft also provides guidance on timelines, fees, and regulatory enforcement to support a more standardized variation process.

More
USA: eMDR – Electronic Medical Device Reporting: FDA Requirements and Submission Process – May/June 2026

USA: eMDR – Electronic Medical Device Reporting: FDA Requirements and Submission Process – May/June 2026

  • 2026-06-26 06:31:01

The FDA's Electronic Medical Device Reporting (eMDR) program requires medical device manufacturers and importers to submit Medical Device Reports (MDRs) electronically for adverse events, malfunctions, and other reportable incidents. The eMDR system improves the efficiency, accuracy, and timeliness of post-market surveillance by enabling electronic submission, processing, and tracking of reports through FDA systems. Manufacturers should establish robust procedures to ensure compliance with eMDR requirements and maintain effective post-market monitoring of device safety and performance.

More
Taiwan: TFDA Releases New Guidance on Good Machine Learning Practice (GMLP) for AI-Based Medical Devices – May/June 2026

Taiwan: TFDA Releases New Guidance on Good Machine Learning Practice (GMLP) for AI-Based Medical Devices – May/June 2026

  • 2026-06-26 06:18:15

On 4 June 2026, the Taiwan Food and Drug Administration (TFDA) announced the Good Machine Learning Practice (GMLP): Development and Management Principles for Artificial Intelligence Medical Devices, providing a lifecycle management framework for AI-enabled medical devices. The guidance outlines 10 key principles covering product design, data quality, clinical evaluation, human oversight, cybersecurity, and post-market monitoring, while further aligning Taiwan's regulatory expectations with international AI medical device frameworks.

More
Philippines: PH FDA Tightens Oversight of Unregistered Aesthetic Injectable Products – May/June 2026

Philippines: PH FDA Tightens Oversight of Unregistered Aesthetic Injectable Products – May/June 2026

  • 2026-06-26 06:03:28

Recent Philippine Food and Drug Administration (PFDA) enforcement actions involving unregistered injectable products highlight the importance of regulatory compliance in the Philippines. This article shares Qualtech's insights on the critical need for strict compliance when expanding into overseas markets, particularly for manufacturers of dermal fillers and other aesthetic injectable products.

More
MALAYSIA: Joint Announcement for Full Implementation of Medical Devic Regulatory Reliance Programmed Between MDA (Malaysia) and Thai FDA (Thailand) – April/May 2026

MALAYSIA: Joint Announcement for Full Implementation of Medical Devic Regulatory Reliance Programmed Between MDA (Malaysia) and Thai FDA (Thailand) – April/May 2026

  • 2026-05-22 06:47:10

The Medical Device Authority (MDA) of Malaysia and the Thailand Food and Drug Administration (Thai FDA) have officially announced the successful completion of a three-month pilot phase, which took place from 1 February 2026 to 30 April 2026. Following this pilot phase, the full implementation of the MDA–Thai FDA Medical Device Regulatory Reliance Programme will now apply to the registration of Class B, Class C, and Class D medical devices.

More